Astegolimab, a selective inhibitor of the IL-33R, ST2, is safe and well tolerated and reduced annual exacerbation rate in a broad range of asthmatic patients, including those that had eosinophil low and poorly controlled severe asthma (Kelsen et al., 2021). The gene discussed is IL1RL1; the disease is asthma.